Older Americans with metastatic breast, colorectal, lung, or prostate cancer are spending an increasing amount of time in the ...

Pelareorep combined with standard chemotherapy achieved a 33% objective response rate in KRAS-mutant MSS mCRC, surpassing ...

Metastatic breast cancer treatment with the combination of PCS6422 and capecitabine (NGC-Cap) may increase the cancer-killing ...

1. Brenner A, Youssef M, Kumthekar P, et al. Rhenium (¹⁸⁶Re) obisbemeda (rhenium nanoliposome, ¹⁸⁶RNL) for the treatment of ...

For patients living with HER2-positive metastatic breast cancer, the recent FDA approval of trastuzumab deruxtecan (brand ...

HER2CLIMB-05 successfully met its primary endpoint of progression-free survival (PFS), with the addition of tucatinib ...

Overall, tucatinib add-on to first-line maintenance therapy for HER2-positive metastatic breast cancer delayed progression by ...

Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine VERO BEACH, Fla., Dec. 17, 2025 ...

The FDA has approved Akeega plus prednisone for adults with deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.

People living with metastatic breast cancer have more treatment options today than ever before. At Fred Hutch Cancer Center, we provide the latest in evidence-based care, including a wide range of ...

The 2025 San Antonio Breast Cancer Symposium brought plenty of data and bold new ideas to the thousands of clinicians, ...

A pioneering strategy is set to revolutionise care for thousands of people living with metastatic cancer in Greater ...